Author

Bornhäuser M

Unknown affiliation - Cited by 36,860

Biography

Dr. Martin Bornhaeuser is an Associate professor in the Department of Internal Medicine I University Hospital Carl Gustav Carus Technische Universität Dresden, Germany. His research topic is  Allogeneic stem cell transplantation, Cellular therapy, Adoptive immunotherapy, Cell biology of mesenchymal and hematopoietic stem cells, Targeted therapy. Currently, Dr. Martin Bornhaeuser is the author/editor/reviewer in several international journals. He published 30 articles in many journals and the articles are informative and got good citations.
Title
Cited by
Year
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial
CM Denkinger, M Janssen, U Schaekel, J Gall, A Leo, P Stelmach, ...Nature Cancer 4 (1), 96-107, 2023202
17
2023
Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1
M Janssen, C Schmidt, PM Bruch, MF Blank, C Rohde, A Waclawiczek, ...Blood, The Journal of the American Society of Hematology 140 (24), 2594-2610, 2022202
15
2022
Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: Diagnostic power and prognostic impact
U Oelschlaegel, L Oelschlaeger, M von Bonin, M Kramer, K Sockel, ...Cytometry Part B: Clinical Cytometry 104 (2), 141-150, 2023202
13
2023
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
JN Eckardt, F Stölzel, D Kunadt, C Röllig, S Stasik, L Wagenführ, ...Journal of Hematology & Oncology 15 (1), 1-13, 2022202
10
2022
Overlapping features of therapy-related and de novo NPM1-mutated AML
J Othman, M Meggendorfer, E Tiacci, C Thiede, R Schlenk, R Dillon, ...Blood, The Journal of the American Society of Hematology 141 (15), 1846-1857, 2023202
9
2023
Study protocol: the OptiScreen-Study: optimized psycho-oncological care—from screening to intervention
T Zimmermann, L Dreismann, V Ginger, M Wenzel, B Hornemann, ...Journal of Cancer Research and Clinical Oncology 149 (3), 1343-134, 2023202
5
2023
Medical microrobots in reproductive medicine from the bench to the clinic
R Nauber, SR Goudu, M Goeckenjan, M Bornhäuser, C Ribeiro, ...Nature Communications 14 (1), 728, 2023202
5
2023
Allogeneic hematopoietic cell transplantation vs standard consolidation chemotherapy in patients with intermediate-risk acute myeloid leukemia: a randomized clinical trial
M Bornhäuser, C Schliemann, J Schetelig, C Röllig, M Kramer, B Glass, ...JAMA oncology 9 (), 519-526, 2023202
4
2023
Mesenchymal stromal cell-associated migrasomes: a new source of chemoattractant for cells of hematopoietic origin
IA Deniz, J Karbanová, M Wobus, M Bornhäuser, P Wimberger, ...Cell Communication and Signaling 21 (1), 1-17, 2023202
4
2023
A dynamic rRNA ribomethylome drives stemness in acute myeloid leukemia
F Zhou, N Aroua, Y Liu, C Rohde, J Cheng, AK Wirth, D Fijalkowska, ...Cancer Discovery 13 (2), 332-37, 2023202
4
2023
Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning
JN Eckardt, C Röllig, K Metzeler, M Kramer, S Stasik, JA Georgi, P Heisig, ...Haematologica 108 (3), 690-70, 2023202
4
2023
Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic
V Arndt, D Doege, S Fröhling, P Albers, H Algül, R Bargou, C Bokemeyer, ...Journal of Cancer Research and Clinical Oncology 149 (2), 91-919, 20220
3
2023
Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial
C Röllig, L Fransecky, M Hanoun, B Steffen, S Kraus, C Schliemann, ...Blood 140 (Supplement 1), 337-338, 0
2
2022
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4
S Kayser, D Martínez-Cuadrón, M Hanoun, F Stölzel, C Gil, HC Reinhardt, ...Haematologica 108 (1), 34, 030
2
2023
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
JN Eckardt, S Stasik, C Röllig, T Sauer, S Scholl, A Hochhaus, M Crysandt, ...Blood Cancer Journal 13 (1), 18, 030
2
2023
Reduced 8-gray compared to standard 12-gray total body irradiation for allogeneic transplantation in first remission acute lymphoblastic leukemia: a study of the acute leukemia …
Reduced 8-gray compared to standard 2-gray total body irradiation for allogeneic transplantation in first remission acute lymphoblastic leukemia: a study of the acute leukemia …A Spyridonidis, M Labopin, B Savani, S Giebel, G Bug, S Schönland, ...HemaSphere 7 (), 2023202
1
2023
Combining Cryogel Architecture and Macromolecular Crowding‐Enhanced Extracellular Matrix Cues to Mimic the Bone Marrow Niche
L Martínez‐Vidal, V Magno, PB Welzel, J Friedrichs, M Bornhäuser, ...Macromolecular Chemistry and Physics 224 (), 2200348, 2023202
1
2023
Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia
F Stölzel, SE Fordham, D Nandana, WY Lin, H Blair, C Elstob, HL Bell, ...JCI insight 8 (2), 2023202
1
2023
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
Impact of IDH and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantationD Kunadt, S Stasik, KH Metzeler, C Röllig, C Schliemann, PA Greif, ...Journal of Hematology & Oncology 5 (), -5, 2022202
1
2022
Die psychoonkologische Versorgungssituation von Patienten mit Weichteilsarkomen
M Eichler, S Singer, L Hentschel, B Hornemann, P Hohenberger, ...Die Onkologie 29 (2), 47-54, 2023202
1
2023

Referred From: https://scholar.google.ca/citations?user=b300fsIAAAAJ&hl=en

Cited by
Citations 36860
h-index 96
i10-index 436
Recommended Journals
Open Access Journals